Radiology, Vol 175, 75-78, Copyright © 1990 by Radiological Society of North America

ARTICLES

Recombinant tissue-type plasminogen activator versus urokinase in peripheral arterial and graft occlusions: a randomized trial

MF Meyerovitz, SZ Goldhaber, K Reagan, JF Polak, K Kandarpa, CJ Grassi, BC Donovan, MA Bettmann and DP Harrington
Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.

A randomized prospective trial was undertaken to compare intraarterial administration of recombinant human tissue-type plasminogen activator (rt-PA) with urokinase (UK) in 32 patients with peripheral arterial or bypass graft occlusions. Sixteen patients were randomized to receive rt- PA and 16 to receive UK. The rt-PA dose was administered as a 10-mg bolus into the thrombus, followed by 5 mg/h for up to 24 hours. The UK dose was administered as a 60,000 IU bolus into the thrombus, followed by 240,000 IU/h for 2 hours, 120,000 IU/h for 2 hours, and 60,000 IU/h for up to 20 hours. Serial arteriograms were obtained at baseline and at 4, 8 or 16, and 24 hours. The endpoint was defined as 95% of greater clot lysis. The cumulative numbers of patients with successful thrombolysis (rt-PA vs UK) were four vs none at 4 hours, seven vs one at 8 hours, seven vs three at 16 hours, and eight vs six at 24 hours. Lysis occurred more rapidly in the rt-PA group (P = .04). Major bleeding complications occurred in five rt-PA patients and two UK patients (P = .39). At 24 hours, fibrinogen levels were significantly lower in the rt-PA group than in the UK group (P = .01). There was no apparent difference in 30-day clinical success.

This article has been cited by other articles:

				E. L. Olvey, G. H. Skrepnek, and P. E. Nolan Jr. Cost-effectiveness of urokinase and alteplase for treatment of acute peripheral artery disease: Comparison in a decision analysis model Am. J. Health Syst. Pharm., August 1, 2008; 65(15): 1435 - 1442. [Abstract] [Full Text] [PDF]

				M. Sobel and R. Verhaeghe Antithrombotic Therapy for Peripheral Artery Occlusive Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 815S - 843S. [Abstract] [Full Text] [PDF]

				G. P. Clagett, M. Sobel, M. R. Jackson, G. Y. H. Lip, M. Tangelder, and R. Verhaeghe Antithrombotic Therapy in Peripheral Arterial Occlusive Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 609S - 626S. [Abstract] [Full Text] [PDF]

				H.-C. Yoon and F. J. Miller Jr. Using a Peptide Inhibitor of the Glycoprotein IIb/IIIa Platelet Receptor: Initial Experience in Patients with Acute Peripheral Arterial Occlusions Am. J. Roentgenol., March 1, 2002; 178(3): 617 - 622. [Abstract] [Full Text] [PDF]

				M. R. Jackson and G. P. Clagett Antithrombotic Therapy in Peripheral Arterial Occlusive Disease Chest, January 1, 2001; 119(1_suppl): 283S - 299S. [Full Text] [PDF]

				M. Baguneid, D. Dodd, P. Fulford, Y. Hadjilucas, M. Bukhari, G. Griffiths, N. Chalmers, M. Walker, and M.G. Walker Management of Acute Nontraumatic Upper Limb Ischemia Angiology, September 1, 1999; 50(9): 715 - 720. [Abstract] [PDF]

				J. I. Weitz, J. Byrne, G. P. Clagett, M. E. Farkouh, J. M. Porter, D. L. Sackett, D. E. Strandness, and L. M. Taylor Diagnosis and Treatment of Chronic Arterial Insufficiency of the Lower Extremities: A Critical Review Circulation, December 1, 1996; 94(11): 3026 - 3049. [Full Text]

				P. Kam, J. Thompson, and J. May Isolated limb perfusion with urokinase in the treatment of extensive vascular thrombosis of the lower limbs Perfusion, November 1, 1994; 9(6): 399 - 404. [Abstract] [PDF]